The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer

Tianjin Medical University

Status: Enrolling

Conditions: Chemotherapy; Pancreas Cancer

Treatments: Other: Adjuvant chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06208436

Adchmopan01

Details and patient eligibility

About

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Enrollment: 250 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021.

Exclusion Criteria: Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.

Trial design

250 participants in 1 patient group

TMUCIH-PDAC

Description:

Between 2010 and 2021, the data of patients who underwent surgical resection and were pathologically diagnosed as PDAC from Tianjin Medical University Cancer Institute and Hospital (TMUCIH) were collected retrospectively.

Treatment:

Other: Adjuvant chemotherapy